Invasive Cardiopulmonary Exercise Testing Identifies Distinctive Hemodynamic Phenotypes in Patients with Interstitial Lung Disease and Exercise Intolerance.
| Title: | Invasive Cardiopulmonary Exercise Testing Identifies Distinctive Hemodynamic Phenotypes in Patients with Interstitial Lung Disease and Exercise Intolerance. |
|---|---|
| Authors: | Balakrishnan B; Division of Pulmonary Medicine, Integrated Hospital Care Institute, Cleveland Clinic, Cleveland, Ohio, USA, p.bala1286@gmail.com.; Marakini A; Division of Pulmonary Medicine, Integrated Hospital Care Institute, Cleveland Clinic, Cleveland, Ohio, USA.; Detloff L; Department of Medicine, Integrated Hospital Care Institute, Cleveland Clinic, Cleveland, Ohio, USA.; Mahalwar G; Department of Medicine, Integrated Hospital Care Institute, Cleveland Clinic, Cleveland, Ohio, USA.; Lane JE; Division of Pulmonary Medicine, Integrated Hospital Care Institute, Cleveland Clinic, Cleveland, Ohio, USA.; Paul D; Division of Pulmonary Medicine, Integrated Hospital Care Institute, Cleveland Clinic, Cleveland, Ohio, USA.; Tonelli AR; Division of Pulmonary Medicine, Integrated Hospital Care Institute, Cleveland Clinic, Cleveland, Ohio, USA. |
| Source: | Respiration; international review of thoracic diseases [Respiration] 2025 Dec 15, pp. 1-12. Date of Electronic Publication: 2025 Dec 15. |
| Publication Model: | Ahead of Print |
| Publication Type: | Journal Article |
| Language: | English |
| Journal Info: | Publisher: Karger Country of Publication: Switzerland NLM ID: 0137356 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1423-0356 (Electronic) Linking ISSN: 00257931 NLM ISO Abbreviation: Respiration Subsets: MEDLINE |
| Imprint Name(s): | Original Publication: Basel, New York, Karger |
| Abstract: | Introduction: Pulmonary vascular abnormalities coexist with interstitial lung disease (ILD), leading to a spectrum of physiologic impairments. We hypothesized that ILD patients with exercise intolerance have a heterogenous hemodynamic profile when assessed by invasive cardiopulmonary exercise testing (iCPET).; Methods: From January 2018 to December 2023, we prospectively performed iCPET for several conditions. The primary outcome of the study was to assess the hemodynamic phenotypes both at rest and during exercise of ILD patients with exercise intolerance, which cannot be fully explained by the severity of ILD.; Results: Of the 43 ILD patients included in the study, 10 (23%) had no pulmonary hypertension (PH), 16 (37%) had no PH with pulmonary vascular resistance (PVR) >2 WU, 7 (16%) had precapillary PH, 7 (16%) had postcapillary or combined pre- and postcapillary PH, and 3 (7%) had unclassified PH. Four (9%) patients had exercise PH. Forced vital capacity, diffusion capacity for carbon monoxide, peak oxygen consumption, and resting partial pressure of oxygen (PaO2) were significantly lower across the no PH to precapillary PH spectrum. Peak exercise PaO2 decreased (97 ± 25, 73 ± 15, and 62 ± 10 mm Hg, p = 0.001) while mPAP/CO slope (1.9 ± 1.1, 3.1 ± 2.1, and 5.1 ± 2.7, p = 0.009) and PAWP/CO slope (0.9 ± 0.7, 0.9 ± 0.7, and 3.0 ± 3.0, p = 0.007) increased from no PH, to no PH with high PVR, to precapillary PH. No associations were noted for gender, presence of fibrotic ILD and scleroderma, and mPAP/CO >3 WU across this spectrum.; Conclusion: Patients with ILD and exercise intolerance have several hemodynamic phenotypes with parameters that reveal worse exercise performance from no PH to no PH with elevated PVR to precapillary PH.; (© 2025 The Author(s). Published by S. Karger AG, Basel.) |
| References: | Front Med (Lausanne). 2024 Jan 17;10:1306032. (PMID: 38298504); Ann Am Thorac Soc. 2021 Apr;18(4):573-581. (PMID: 33792518); Circulation. 2019 Aug 20;140(8):705-707. (PMID: 31424987); Cardiovasc Diagn Ther. 2024 Oct 31;14(5):911-920. (PMID: 39513135); Respir Med. 2017 Mar;124:65-71. (PMID: 28284324); Pulm Circ. 2023 Apr 01;13(2):e12213. (PMID: 37025209); Ann Am Thorac Soc. 2023 Dec;20(12):1752-1759. (PMID: 37561068); Pulm Circ. 2024 Jan 11;14(1):e12334. (PMID: 38223421); Am J Respir Crit Care Med. 2022 Jan 15;205(2):198-207. (PMID: 34767495); Pulm Circ. 2022 Oct 01;12(4):e12141. (PMID: 36225536); Eur Respir J. 2024 Oct 31;64(4):. (PMID: 39209469); Am J Respir Crit Care Med. 2018 Feb 15;197(4):509-516. (PMID: 29099619); Eur Respir J. 2016 Apr;47(4):1179-88. (PMID: 26677941); N Engl J Med. 2021 Jan 28;384(4):325-334. (PMID: 33440084); Respir Med. 2024 Nov-Dec;234:107835. (PMID: 39426436); Eur Respir Rev. 2019 Feb 27;28(151):. (PMID: 30814139); Ann Thorac Surg. 2016 Jan;101(1):246-52. (PMID: 26319484); Chest. 2006 Mar;129(3):746-52. (PMID: 16537877); Circulation. 2013 Sep 24;128(13):1470-9. (PMID: 24060943); Eur Respir J. 2019 Jan 24;53(1):. (PMID: 30545968); Eur Respir J. 2002 Nov;20(5):1314-31. (PMID: 12449189); BMJ. 2007 Oct 20;335(7624):806-8. (PMID: 17947786); Pulm Circ. 2023 Aug 08;13(3):e12273. (PMID: 37564922); J Cardiovasc Pharmacol Ther. 2019 Jul;24(4):334-354. (PMID: 30773044); Chest. 2022 Jul;162(1):145-155. (PMID: 35176276); Lancet Respir Med. 2020 Sep;8(9):873-884. (PMID: 32730752); Arthritis Rheum. 2013 Apr;65(4):1074-84. (PMID: 23280155); Eur Respir J. 2022 Oct 13;60(4):. (PMID: 35332069); Circulation. 2012 Jan 17;125(2):289-97. (PMID: 22131357); Pulm Circ. 2013 Dec;3(4):916-25. (PMID: 25006408); Eur Respir J. 2023 Jan 6;61(1):. (PMID: 36028254); Am J Respir Crit Care Med. 2022 May 1;205(9):e18-e47. (PMID: 35486072); Chest. 2016 Feb;149(2):353-361. (PMID: 26134583); Eur Respir J. 2023 Jun 29;61(6):. (PMID: 37080567); PLoS One. 2024 Feb 6;19(2):e0286423. (PMID: 38319942); Eur Respir J. 2015 Sep;46(3):728-37. (PMID: 26022955); Thorax. 2024 Apr 15;79(5):422-429. (PMID: 38316550); Circulation. 2016 Mar 29;133(13):1240-8. (PMID: 26873944); Eur Heart J. 2023 Nov 21;44(44):4678-4691. (PMID: 37619574); Respir Med. 2024 Nov;233:107775. (PMID: 39147212); N Engl J Med. 2020 Sep 3;383(10):958-968. (PMID: 32877584); Eur J Prev Cardiol. 2024 Sep 6;31(12):1550-1552. (PMID: 38629662); Ann Rheum Dis. 2012 Aug;71(8):1335-42. (PMID: 22307943); Diagnostics (Basel). 2023 Jul 13;13(14):. (PMID: 37510098); Eur Respir J. 2022 Aug 4;60(2):. (PMID: 35680147); Eur Respir Rev. 2018 Dec 21;27(150):. (PMID: 30578335); Chest. 2019 May;155(5):982-990. (PMID: 30826305); Breathe (Sheff). 2022 Dec;18(4):220232. (PMID: 36865934); Chest. 2020 Jul;158(1):350-358. (PMID: 32173491); Pulm Circ. 2018 Jul-Sep;8(3):2045894018787381. (PMID: 29916285); Eur Respir J. 2024 Nov 27;64(6):. (PMID: 39603672) |
| Contributed Indexing: | Keywords: Cardiopulmonary exercise test; Exercise intolerance; Interstitial lung disease; Pulmonary hypertension; Right heart catheterization |
| Entry Date(s): | Date Created: 20251215 Latest Revision: 20260131 |
| Update Code: | 20260131 |
| PubMed Central ID: | PMC12854684 |
| DOI: | 10.1159/000550078 |
| PMID: | 41397010 |
| Database: | MEDLINE |
Journal Article